We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Children's National Health System today announced the opening of a unique chimeric antigen receptor (CAR) T-cell immunotherapy trial for pediatric patients with relapsed positive acute lymphoblastic leukemia (ALL).